No Data
No Data
Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) High Institutional Ownership Speaks for Itself as Stock Continues to Impress, up 17% Over Last Week
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients With RARA Gene Overexpression
Download as PDF June 13, 2024 -- Three medical experts will join members of Syros' leadership team to provide an overview of HR-MDS patient management, perspectives on the current and future treatme
HC Wainwright & Co. Reiterates Buy on Syros Pharmaceuticals, Maintains $15 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Syros Pharmaceuticals (NASDAQ:SYRS) with a Buy and maintains $15 price target.
Optimistic Outlook for Syros Pharmaceuticals With Promising Clinical Trials and Regulatory Advancements
Q1 2024 Syros Pharmaceuticals Inc Earnings Call
Earnings Call Summary | Syros Pharmaceuticals(SYRS.US) Q1 2024 Earnings Conference
The following is a summary of the Syros Pharmaceuticals, Inc. (SYRS) Q1 2024 Earnings Call Transcript:Financial Performance:Syros reported no revenue in Q1 2024 due to the termination of its collabora
No Data